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1. Introduction 
Carotid intervention for the amelioration of symptoms due to carotid stenosis has been a 
controversial therapeutic concept for much of its history. Operative carotid surgery 
(carotid endarterectomy) underwent considerable turmoil and challenge during the late 
20th century, eventually becoming a generally accepted approach in the management of 
symptomatic critical carotid artery stenosis. A similar circumstance currently confronts 
carotid angioplasty. Carotid endarterectomy (CEA) now represents the clinical standard 
against which any carotid intervention is compared and carotid angioplasty must 
“measure up” to this reference procedure. However, it must be recognized that the time 
line for acceptance of CEA measured approximately 40 years suggesting that the clinical 
community must exercise patience in the evaluation of carotid angioplasty which enjoys a 
relatively short history. Conversely, there is considerable vested interest by several 
specialties for carotid angioplasty to be accepted (cardiology, radiology) or rejected 
(vascular surgery) indicating the need for critical analysis of this procedure’s efficacy. 
This process of procedure assessment remains a difficult task in view of the constantly 
changing technological advances that surround this field. This chapter focuses on the key 
elements of technique and clinical experience which represent the status of carotid 
angioplasty today. 
2. History 
The association of carotid artery blood flow to the brain as a vital element to  
sustain neurologic function dates back to Hippocrates (Figure). As a corollary, it has 
become accepted that atherosclerotic disease of the carotid artery is associated with 
stroke. This concept was first described by Ramsay Hunt in 1914 and subsequently 
popularized as one of the most significant risk factors for developing stroke. It wasn’t 
until the 1950’s, when durable reconstructive carotid surgery was described and further 
refined and popularized by Debakey, Eastcott, Rob, Thompson, Moore, Baker and  
Wylie, that the field of carotid intervention was popularized. Some of the landmark  
large randomized controlled trials like North American Symptomatic Carotid 
Endarterectomy (NASCET)1, Asymptomatic Carotid Atherosclerosis Study (ACAS)2 and 
European Carotid Surgery Trial (ECST)3 showed statistically significant reductions in 
stroke in the patients undergoing carotid endarterectomy versus medical treatment alone. 
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Currently, there are approximately 165,000 carotid endarterectomy (CEA) procedures 
performed across United States annually and this procedure is considered the “gold 
standard” for revascularization of the internal carotid artery due to atherosclerotic 
stenosis. 
 
 
Adapted From Hippocrates to Palmaz-Schatz, the history of carotid surgery. 4 
Robicsek F, Roush TS, Cook JW, Reames MK. Eur J Vasc Endovasc Surg. 2004 Apr;27(4): 
389-97.  
Moniz described carotid and cerebral angiography in 1927 and thereafter, further 
improvements in the extracranial carotid imaging facilitated more patients being 
diagnosed with occlusive carotid diseases and hence treatment advancement. Debakey 
and his coworkers described intraluminal angioplasty of the internal carotid artery in 
1968 for fibromuscular dysplasia.5 Percutaneous transluminal angioplasty of carotid 
artery was described in 1977 by Mathias͸ and subsequently Diethrich͹ reported the first 
large series of carotid angioplasty and stenting in 1995, although the risk of neurological 
complication was as high as 10.7% in his report. Subsequently, multiple technical 
advances have taken place in percutaneous carotid artery interventions including stent 
augmentation of carotid angioplasty, routine use of cerebral embolic protection and 
improved patient selection.  
Carotid angioplasty and stenting (CAS) provides a few advantages over traditional  
CEA including avoidance of a neck incision, general anesthesia and freedom from cranial 
nerve injuries. These benefits have sustained the evolution of CAS over the last 20-30  
years.  
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3. Technical aspects of carotid angioplasty and stenting 
Key for successful endoluminal intervention is patient evaluation and proper patient 
selection, choice of optimum vascular access site, a thorough evaluation of the access route, 
any anatomic or morphologic anomalies, appropriate selection of devices and accurate 
sizing of the target lesion and vessels.  
Pre-procedural assessment of carotid artery disease is obtained by duplex ultrasound (DU). 
DU allows an assessment of the degrees of stenosis and extent of calcification. Highly 
calcified lesions may be more embologenic or unyielding to balloon angioplasty resulting in 
a suboptimal dilatation. Further information on the target lesion may be obtained by 
magnetic resonance (MR) or computed tomographic (CT) arteriography. These two imaging 
modalities are useful confirmatory studies following duplex imaging and offer an 
assessment of unsuspected occlusive disease outside the DU imaging window. Furthermore, 
these non-invasive means evaluate access site, aortic arch morphology and any incidental 
pathology in the access route which are invaluable in the planning of a procedure.  
4. Aortic arch configuration 
Initially, a 4 or 5 Fr sheath access is obtained in the common femoral artery. A flush 
pigtail catheter may be positioned in the ascending aorta for the initial arch aortogram 
which is performed in left anterior oblique (LAO) position. Depending on the degree of 
tortuosity and configuration of the aortic arch, we like to have between 30 degrees to as 
much as 60 degrees of LAO projection. The performance of the arch angiogram is useful 
to identify the target vessel origin. In difficult anatomic arrangements, the aortogram is 
very helpful but it may also increase procedure morbidity. Utilizing diffusion weighted 
MRI imaging, silent microembolic lesions are detectable in up to two-thirds of patients 
undergoing CAS8. At least half of these lesions can be identified in the cerebral 
hemisphere contralateral to the target lesion. This suggests that manipulation of devices, 
including diagnostic catheters used for arch angiography, are a substantial source of 
embolic events during CAS. 
The aortic arch configuration varies due to multiple patient factors. Probably the dominant 
factor is age since the aorta tends to elongate with increasing age contributing to a 
worsening of the arch type. There are mainly three arch types depending on the 
radiographic morphology (Figure).  
5. Diagnostic catheters 
Safe selective cannulation of the great vessels is the rate-limiting step. Usually the 
appropriate diagnostic catheters are available in 100 cm to 125 cm lengths. The longer 
lengths are required should one use the telescoping technique (vida infra). 
For the Type I aortic arch, the standard angled catheters like the angle taper Glidecath® 
(Terumo Medical Corporation, Somerset, NJ, USA) or a Berenstein catheter (Boston 
Scientific, Natick, MA, USA) or Headhunter or JB 1 (Cook Medical, Bloomington, IN, USA) 
are usually successful.  
For more challenging aortic arch morphology, with types II and III configuration, reverse-
curve catheters like Simmons type catheters (I or II), JB 2 or the VTK catheter (Cook Medical, 
Bloomington, IN, USA) may be used. 
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A Type IV arch is a term that may be applied to an exaggerated Type III arch with severe 
angulation of the great vessels. 
Type I – The great vessels originate 
from the same horizontal plane of 
the outer curvature of the arch  
Type II – Innominate artery 
originates between the horizontal 
planes of outer and inner curvature 
of the arch 
Type III – Innominate artery 
originates below the horizontal 
plane of inner curvature of the arch 
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Glidecath® 
 
 
These are the configurations of some of the catheters commonly used in the carotid 
angioplasty procedure. 
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6. Sheath access 
Positioning of a sheath in the CCA is a prerequisite to CAS. Typically, this requires 
placement of a diagnostic catheter into the CCA followed by advancement of a glide-wire 
into the ECA. This allows introduction of the catheter into the ECA followed by a wire 
exchange for a stiff wire forming the guide for a 6 Fr Shuttle sheath. Occasionally, the ECA 
is occluded or severely diseased requiring the use of a stable stiff wire access into common 
carotid artery (CCA) alone and a 6 Fr sheath is advanced and parked into proximal CCA. 
7. Cannulation of internal carotid artery 
After obtaining stable sheath access into proximal CCA, the embolic protection device (EPD) 
is deployed into the appropriate position. The pros and cons of different cerebral EPDs are 
discussed in next section.  
The different approches of obtaining ICA access depend upon the degree of stenosis, 
amount of tortuosity and type of EPD used. Usual access to the ICA is obtained with a 
standard 0.014” wire or EPD dedicated wire followed by delivery of the balloon and stent 
system. 
8. Telescoping catheter technique 
Positioning of the Shuttle sheath system into the CCA is a prerequisite for the CAS 
procedure. Typically, this is performed over a stiff wire anchored in the ECA. However, 
advancement of the stiff wire into the CCA through a diagnostic catheter may be a 
challenge. If tortuous anatomy prevents this maneuver, a softer, 125 cm 6 or 6.5 Fr catheter 
is used to replace the obturator of the Shuttle sheath. The additional 35 cm lead portion of 
this catheter which is telescoped into the 90 cm Shuttle serves as a sufficient support over 
which to slide the sheath once the catheter tip is introduced into the CCA. Thus, the inner 
catheter effectively serves as a “stiff guide”. 
9. Right brachial/axillary artery access technique (double wire technique) 
Access to the right carotid system can be achieved under essentially all anatomically 
difficult circumstances with this technique. This approach has been successful even with an 
exaggerated Type III aortic arch configuration (effectively a Type IV arch). The technique 
requires gaining access to the brachial or axillary artery on the right with passage of an 
exchange length glide wire retrograde into the thoracic aorta. The wire is snared from a 
femoral access point for through and through wire control. A 7 or 8 Fr sheath is now 
advanced into the innominate artery. The wire may be changed out for a smaller wire to 
reduce occupied space within the sheath while stabilizing it. This is then followed by the 
transfemoral advancement of a second steerable 0.014” wire into the CCA. The second wire 
now permits the delivery of a cerebral protection system and completion of the CAS 
procedure.  
10. Transtemporal technique 
Access to the CCA can be quite difficult if the carotid anatomy is tortuous or the aortic arch 
type is unfavorable. The transtemporal approach may be used on either side but it has its 
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greatest utility on the left since the right CCA can be cannulated using the double wire 
technique noted above. The transtemporal approach involves ultrasound guided access or 
direct dissection of the superficial temporal artery followed by retrograde placement of a 
coronary wire into the aorta where it is snared from the femoral artery. This provides 
through and through access permitting advancement of a Shuttle sheath into proper 
position for the CAS procedure. The remainder of the procedure is then performed in the 
usual fashion. 
11. Ultra-critical stenosis 
Sometimes the standard 0.014” wire is not successful in traversing an ultra-critical 
stenosis, in which case a 0.012” Headliner® Glidewire® (45 degrees, 200 cm) (Terumo 
Medical Corporation, Somerset, NJ, USA), supported by 1.9 Fr (0.026”) Prowler® 
microcatheter (Cordis, Miami Lakes, FL, USA) may be successful. Following traversal  
of the lesion with the microcatheter, the 0.012” wire is replaced with a more supportive 
0.014” wire which can be parked in the treatment area. The new wire may now be used  
to deliver a balloon, EPD or a flow arrest/reversal system (vida infra) for completion of  
the CAS. 9 
 
 
This figure shows a pre-occlusive lesion of the right internal carotid artery which would not 
accept a 0.014” wire. 
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The lesion has been passed using an 0.012” wire followed by replacement with an 0.014” 
wire and placement of a MOMA flow arrest device within the external carotid artery  
balloon inflated (long arrow).  
 
The ICA angioplasty is complete. The MOMA flow arrest device is still in place with the 
ECA and CCA balloons deflated and flow re-established to the brain. 
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12. Transcervical occlusion and protective shunting technique 
This technique uses a partially open operative approach. The procedure is performed under 
local anesthesia utilizing a small incision just above the clavicle. A large (9 Fr) and medium 
(6 Fr) sheath are introduced into the CCA directed in a cephalad orientation through the 
incision. Additionally, a 6 Fr sheath is introduced into the jugular vein directed caudally. An 
over-the-wire fogerty catheter is used to occlude the external carotid artery and the 
proximal CCA is clamped following anticoagulation. Flow reversal in the carotid system is 
established by connecting the sideports of the 9 Fr arterial and 6 Fr venous sheaths and flow 
direction is verified using a small injection of contrast. Now, the angioplasty is performed 
through the 9 Fr sheath and any loose debris that results is carried into the venous system or 
trapped by any interposed filter. The arterial puncture sites are sutured at the time of final 
sheath removal. This approach appears fairly labor intensive within a small field and the use 
of a partially open portion of the angioplasty procedure seems to defeat the minimally 
invasive nature of CAS. Nonetheless, it has been suggested as a reliable means of controlling 
embolization. 
13. Review of literature 
Mathias first described the percutaneous carotid artery angioplasty (CA) technique in 
1977.10 Subsequently he reported a case series of 3 high surgical risk patients undergoing 
percutaneous carotid angioplasty.11 During this time, percutaneous carotid intervention was 
limited to fibromuscular dysplasia and was not applied to atherosclerotic diseases due to 
risk of embolic events and secondly, CEA was considered a very safe procedure and its 
utilization was widespread. There were occasional case reports of CA, but it wasn’t until 
1990’s when this technique was more systematically studied for its feasibility, safety and 
outcomes. The summary of early clinical studies is shown in Table 1. The most feared 
complication of CA is embolic phenomenon and evidence of early and delayed embolization 
after percutaneous CA was reported by Markus et al. 12  
 
 
Study number 
(Follow-up) 
Technical 
success 
Stroke 
Overall complications 
(MI/Stroke/Death) 
Diethrich EB13 (1996) 110 (7.6 months) 99% 12 (10.9%) 12 (10.9%) 
Roubin GS14 (1996) 146 (6 months) 99% 9 (6%) 11(7.5%) 
Gil-Peralta A15 (1996) 85 (18.7 months) 91.8% 7 (8.6%) 7 (8.6%) 
Yadav JS16 (1997) 107 (6 months) 100% 9 (8.4%) 10(9.3%) 
Jordan WD, Jr17 (1997) 107 (6 months) NA 9 (8.4%) 10 (9.3%) 
Vozzi CR18 (1997) 22 (10 months) NA 2 (9%) 2 (9%) 
Teitelbaum GP19 (1998) 25 (6 months) 96.2% 2 (7.7%) 6 (27%) 
Table 1. 
In 1992, Brown20 reviewed approximately 100 cases reported in the literature with stroke 
rate of 4%. In May 1998, Wholey21 published a review of 2,048 cases of carotid stents across 
24 centers world-wide and reported a 98.6% technical success rate. Also the complication 
rates were 3.08% for minor strokes, 1.32% major strokes and 1.37% peri-procedural 
mortality. The 6-month re-stenosis rate was 4.8% by duplex-ultrasound or angiographic 
method. The stents being utilized for carotid stenting at the time were Palmaz (Cordis) or 
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Palmaz-Schatz (Johnson and Johnson) balloon expandable stents (53%), followed by 
Wallstent (Schneider, Minneapolis, MN) (39%), Strecker (8%) and Inegra (1%) (Medi-Tech) 
stents. Subsequently, he reported updated data for 5,210 cases across 36 centers in June 2000. 
This showed a rapid rise in global popularity of this procedure. The incidence of major and 
minor stroke remained 1.49% and 2.72%. This review observed lower stroke rates in the 
centers with more than 50 procedures performed indicating the importance of a learning 
curve. Overall procedure-related complication rates declined from 5.72% in 1998 to 4.75% in 
2000. Since the cerebral protection technology had not yet evolved, these results derived 
from “unprotected” procedures. 
Theron et al22 first reported the use of cerebral embolic protection in carotid artery angioplasty 
and stenting procedures. There were no procedure related complications in 136 cases of 
carotid artery stenting with use of the cerebral embolic protection for atherosclerotic stenosis. 
The Carotid Revascularization using Endarterectomy or Stenting Systems (CaRESS)23 was a 
non-randomized prospective trial designed for high-risk patients with or without 
symptoms. Total of 397 patients were studied and the outcomes at 4-years showed a stroke 
incidence of 9.6% in CAS group versus 8.6% in CEA group (p=0.444) and an overall 
complication (death/stroke) rate of 26.5% in CEA versus 21.8% (p=0.361) in CAS. However, 
at the long-term follow-up, there were significantly higher re-stenosis and re-intervention 
rates in the CAS arm. 
14. Randomized controlled trials 
14.1 CAVATAS 
In 1996, the European Carotid Angioplasty trial group reported the rationale, design and 
protocol of the first multicenter randomized trial, the Carotid and Vertebral Artery 
Transluminal Angioplasty Study (CAVATAS).24 Preceding this trial, a single center trial in 
the UK was stopped after enrolling 20 patients due to unacceptable rate of stroke in the 
carotid angioplasty arm (7/10 patients).25 The CAVATAS trial involved 22 centers across 
Europe, Canada and Australia and the patient enrollment was between March 1992 and July 
1997. Five hundred and four patients were randomized to either CEA or CAS. The majority 
of patients (90%) in both arms had symptoms within 6 months of randomization and 
exhibited >70% carotid stenosis. Because the stents suitable for CAS were developed during 
the course of this study, all the patients before 1994 had primary balloon angioplasty alone 
versus the cases thereafter, which utilized stenting with Wallstent (Schneider, Minneapolis, 
MN), Streker (Medi-Tech, USA) and Palmaz (Johnson and Johnson, USA) stents. High-risk 
patients were excluded from the study. The major stroke and death rates were not 
statistically significantly different between two groups (30-day: 10% for CAS versus 10% for 
CEA; 3-years: 14.3% in CAS versus 14.2% in CEA). The primary limitation of this study is 
that very low number of patients (26%) who underwent carotid artery stenting and that the 
stroke and death rates were unusually high. However, subgroup analysis showed the 
incidence of stroke was only 2% in the stented patients, which lead to more widespread use 
of stent application after balloon angioplasty of a carotid artery stenosis. 
15. WALLSTENT
26
 
The Carotid WALLSTENT trial enrolled 223 patients with symptomatic carotid artery 
stenosis > 60%. No cerebral embolic protection was used. The trial was stopped due to 
unacceptably high risk of stroke in CAS group (12.1 %) versus CEA (4.5%, P=0.022). 
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16. Stenting and Angioplasty with Protection of the Patients at High Risk for 
Endarterectomy (SAPPHIRE)
27
 
This multicenter, industry-supported randomized trial enrolled 747 patients from 29 centers 
between 2000 and 2002. The major “high-risk”criteria were significant cardiac or pulmonary 
disease, contralateral carotid occlusion, prior neck radiation or radical neck surgery, 
recurrent stenosis, contralateral recurrent laryngeal nerve palsy or age greater than 80 years. 
The study showed that CAS was non-inferior to CEA when evaluating the cumulative 
incidence of major stroke, MI or death in 30-day period and at 1-year.  
17. Stent-supported Percutaneous Angioplasty of the Carotid artery versus 
Endarterectomy (SPACE)
28
 
The SPACE trial was designed as non-inferiority trial for CAS versus CEA. 1214 patients 
with symptomatic high grade stenosis of carotid artery (>70%) were randomized into CAS 
or CEA between March 2001 and February 2006. The primary end-point of ipsilateral stroke 
or death rate was 6.45% in CEA group versus 6.92% in CAS group which did not reach the 
statistical significance level (p=0.09) for non-inferiority for CAS. At 2-year follow-up, the 
overall mortality was 6.3% in CAS versus 5% in CEA (p=0.68), and the ipsilateral ischemic 
stroke rate was 2.2% vs 1.9%. However, recurrent stenosis (>70% by ultrasound criteria) was 
10.7% in CAS versus 4.6% in CEA group (p=0.0009). The subgroup analysis showed patients 
greater than 68 years of age had higher event rates with CAS compared to CEA, whereas the 
younger patients did better with CAS compared to CEA. 
18. Endarterectomy Versus Angioplasty in patients with Symptomatic Severe 
Carotid Stenosis (EVA-3S) trial
29
 
This trial was a French multicenter, prospective randomized non-inferiority trial. The 
patient enrollment started in November 2000 and ended in September 2005. A total of 527 
patients were enrolled and randomized into two arms. All the CAS cases after January 2003 
were done with approved EPDs at the time, which left initial 73 cases being done without 
any cerebral protection. The 30-day risk of stroke or death was 3.9% in CEA group versus 
9.6% in CAS group, and risk of any peri-procedural disabling stroke or death was 1.5% in 
CEA group versus 3.4% in CAS group. The 4-year hazard ratio (HR) of any disabling or fatal 
stroke or death was 2.0 (p=0.17) slightly favoring endarterectomy. Although the peri-
procedural risk was unusually higher in the stenting group, overall long-term secondary 
prevention of stroke was similar in both arms. The major criticism of this study was that 
despite a requirement of a minimum procedure volume performed prior to enrollment in 
the study as an operator, overall operator experience was too limited and may have 
influenced the outcomes. 
19. The International Carotid Stenting Study (ICSS)
30
 
The ICSS study, also known as CAVATAS-2, was designed. A meta-analysis of 3 trials, 
EVA-3S (2008), SPACE (2008) and the ICSS (2010) showed significantly lower event rate in 
the CEA group (OR 1.73, 95% CI: 1.29 – 2.32)20. Age, greater than 70 years, was a risk factor 
for poorer outcomes with CAS (12%) compared to CEA (5.9%), RR = 2.04. However, the 
patients younger than 70 years had no difference in outcomes.31 
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20. Carotid Revascularization Endarterectomy versus Stenting Trial 
(CREST)
32
 
This North American prospective randomized controlled trial enrolled 2502 patients from 117 
centers (symptomatic and asymptomatic). The primary end-points of any stroke, MI or death 
were similar in both groups of CEA (6.8%) and CAS (7.2%). Although there was a lower 
incidence of MI in the CAS group versus lower stroke rate in the CEA group, these rates did 
not reach statistical significance. Also the younger patients had slightly better outcomes with 
CAS whereas the older patients did slightly better after CEA. At one year, subgroup analysis 
revealed that stroke had a lasting effect on quality of life as opposed to the effects of MI. 
Nonetheless, overall, both procedures were safe when done by a skilled operator. 
21. Cerebral embolic protection devices 
The first safety and feasibility study of the ICA filter devices for cerebral embolic protection was 
done by Reimers et al.33 The 3-types of the filter devices used in that study are shown below. 
 
           
Subsequently, the EPD field has expanded with the addition of other filtration systems such 
as those shown below. All of these devices are based upon a similar principal of flow-
through filtration. 
Angioguard
Neuroshield / 
Emboshield 
FilterWire EX 
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Overall, there are three major functional principles upon which all EPDs are based. (1) Distal 
ICA balloon occlusion with flow arrest (2) filtration with continuous flow through (as noted 
in the above figures), and (3) proximal balloon occlusion with flow stagnation or flow 
reversal. The pros and cons of these devices are enumerated in Table 2. 
Rx Accunet 
Spider
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Type Pros Cons 
Currently available 
in Market in the US 
Filter Maintains flow throughout 
the procedure 
 
Can perform angiogram 
during the procedure 
Risk of embolism 
while traversing the 
lesion 
 
Technically difficult 
in tortuous vessels 
 
Risk of 
microembolism 
(smaller than pore 
size of the filter) 
 
Risk of filter 
thrombosis 
• Rx Accunet 
• Filter-wire 
• Angioguard 
• Emboshield 
• Spider 
Distal ICA 
occlusion 
Offers complete distal 
embolic protection 
Risk of embolism 
while traversing the 
lesion 
 
Potential for arterial 
injury by balloon 
 
Inability of some 
patients to tolerate 
ICA occlusion 
 
Inability to perform 
angiogram during 
the procedure 
• GuardWire 
Proximal 
occlusion 
Does not require traversing 
the lesion unprotected 
 
Offers complete distal 
embolic protection 
Complete flow 
arrest or reversal 
during the 
procedure 
 
Potential for arterial 
injury by balloon 
 
Cerebral Intolerance
• MO.MA 
• PAES (Parodi 
antiembolism 
system) 
Table 2. 
22. Filter protection 
All filter devices have similar design. The filter is mounted on a 0.014” wire with floppy tip. 
The filter is made up from nitinol (nickel-titanium alloy) covered with polyurethane 
membrane. The porous size of the filter ranges from 30 to 140 microns. Each filter comes in 
with its own deployment and retrieval sheaths. The filter basket and the sheath are flushed 
carefully with heparinized saline with particular attention to avoid any air-bubbles. Once 
the filter is deployed in the distal straight portion of the ICA, the more proximal diseased 
area is treated over the 0.014” wire. The size of the filter is chosen considering the luminal 
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diameter of the distal ICA. At the conclusion of the procedure, the filter is retrieved and 
then the entire system is removed. The currently available filter-devices have a crossing 
profile between 3Fr and 4Fr and accommodate the vessels from 3mm to 7mm diameter.  
23. Flow arrest or flow reversal technique 
Embolic protection during CAS can be accomplished with carotid flow arrest or reversal. The 
MOMA device is a 9 Fr sheath incorporating a small compliant balloon introduced into the 
ECA and a larger balloon located on the distal main body of the device used for CCA 
occlusion. Intubation of the ECA is performed using a 0.035” wire placed during a standard 
initial approach. The ECA wire serves as a guide for initial device placement. Following 
anticoagulation, the ECA and CCA balloons are inflated providing for carotid flow arrest. Any 
standard 0.014” wire may now be used to deliver angioplasty balloons and stents to the target 
lesion. An advantage to this system is that the working wire does not need to be advanced 
deep into the ICA territory thereby making this a favorable method when there is severe 
tortuosity to the ICA which will not accept distally placed filtration EPDs. Debris in the carotid 
bulb and ICA is aspirated at the conclusion of the procedure prior to balloon deflation.  
Initial data in a multicenter, intention-to-treat trial, ARMOUR Trial(Proximal Protection 
with the MO.MA Device During Carotid Stenting), showed that the major 30-day event rate 
(major cardiac and cerebrovascular) was 2.7% and 30-day major stroke rate was 0.9% in the 
patients undergoing CAS with MO.MA cerebral protection device.34  
 
 
MO.MA device. (Source: Invatec Inc., Italy)  
Flow reversal uses a similar principal of ECA and CCA occlusion during the angioplasty 
procedure but with dynamic flow reversal of blood from the carotid bulb into the femoral 
vein via a system side port. The flow reversal is encouraged by the higher arterial back 
pressure from the ICA compared to the venous system once the balloon system is inflated. 
This device is called the Parodi antiembolism system (PAES). Both devices serve the role of 
EPD as well as access sheath. 
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24. Neurorescue during carotid artery stenting 
24.1 Procedural embolization 
Embolization can occur during the carotid artery stenting procedure and that can be in the 
form of micro- or macro-embolization. However, the risk of embolization is particularly 
high during the diagnostic phase, deployment of EPD period and during retrieval of the 
EPD. Most cases with micro-embolization are asymptomatic at the time of the procedure 
and in the immediate post-procedural phase, but their impact on long-term functional 
outcome (eg., cognitive function) is largely unknown.  
The risk of embolization can be minimized by peri-procedural antiplatelet therapy (oral or 
intravenous GPIIB-IIIA inhibitors) and anticoagulation. These agents reduce platelet 
aggregation when subintimal tissue or stent material is exposed to the blood system during 
CAS. However, should macro-embolization occur, mainly due to technical error or failure of 
EPD, one should be prepared with mechanical retrieval/aspiration systems or catheter-
directed thrombolysis.  
24.2 Thrombosis 
Thrombosis during the CAS procedure is associated with the use of EPDs. This is usually 
treated with direct aspiration of thrombus and/or direct administration of a thrombolytic 
(ie. Alteplase) or GPIIb-IIIa inhibitor intra-arterially, if possible. Also, distal embolization 
can be prevented by adopting an incomplete filter-retrieval technique in which case the filter 
retrieval system is not closed completely upon removal in order to prevent thrombus from 
being squeezed out of the system.  
Acute stent thrombosis is rare (< 2%) and can be further minimized by appropriate 
periprocedural antiplatelet and anticoagulation strategy. The treatment consists of direct 
infusion of thrombolytic agent and/or GPIIb-IIIa inhibitor. This latter maneuver must be 
weighed against the risk of precipitating embolization during the lysis of an established ICA 
clot. In rare circumstances, when endoluminal techniques fail, the patient should 
immediately be taken to operating room and thrombectomy should be performed after 
appropriate anticoagulation and obtaining distal control to prevent progression of 
thrombosis and distal embolization. 
24.3 Dissection 
Dissection is fortunately a rare phenomenon and is usually related to stent insertion and/or 
balloon dilation. If the dissection does not limit the flow-lumen significantly, “wait-and-
observe” strategy can be employed with or without use of continued anticoagulation. In 
case of significant flow-limiting dissection, the deployment of second stent may be 
advocated versus open surgical repair. 
25. CAS surveillance 
25.1 Carotid restenosis 
The need for post-procedure surveillance is typically recommended by physicians who 
perform CAS. Surveillance options include duplex ultrasound (DU), MRA and CTA. MRA 
suffers from signal degradation due to the presence of a metallic stent and CTA involves 
significant ionizing radiation and the use of iodinated contrast, which may cause 
nephrotoxicity and allergic reactions35. Consequently, because of the absence of risk, DU 
surveillance after CAS has become the standard. 
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Post-procedure sonography is performed in order to (1) identify undetected procedural 
faults associated with residual stenosis, (2) evaluate the occurrence of neointimal 
hyperplasia at the stented site, and (3) monitor the progression of contralateral disease. The 
incidence of significant contralateral disease ranges 25-50% making this the most compelling 
reason for ongoing duplex surveillance. Assessment of restenosis at the angioplasty site 
represents the second most frequent need for longitudinal surveillance.35 
Risk factors for restenosis after CAS largely remain undefined. When various factors are 
analyzed, a history of head and neck cancer and prior carotid endarterectomy (CEA) were 
found to be marginally significant for the development of early in-stent restenosis (ISR).36,37 
The time line for the occurrence of ISR is somewhat variable but the majority (>70%) of these 
cases are identified within 12 months following the index procedure3. However, this disease 
process may be ongoing as evidenced by an increasing incidence over a five year follow-up. 
Lal et al38, reported ISR rates of 2.7% and 6.4% at 1 and 5 years, respectively. These data utilize 
80% stenosis as a measure of disease with this frequency rising if lower degrees of restenosis 
criteria are selected. Interestingly, ISR may regress over time but the temporal profile of this 
process as well as factors predictive of regression remain undefined. 
25.2 Duplex ultrasound criteria 
The baseline post-procedural duplex velocities for stented vessels tend to exhibit higher 
values than unstented vessels of normal luminal caliber. This may result from either 
under dilatation of the ICA during CAS or a change in the mechanical properties of the 
ICA. A common notion is that the purpose of balloon dilatation is to ensure an adequate 
ICA lumen and not an anatomically cosmetic perfect result. This conservative approach 
may predispose to a minor residual stenosis exemplified by a peak systolic velocity (PSV) 
higher than normal. Alternatively, some authorities have reported that the introduction of 
a stent into the carotid bulb and ICA alters the biomechanical properties of the vessel 
resulting in a stent-arterial complex with decreased compliance. This translates into an 
elevated PSV because energy normally applied to dilate the artery is now expended as 
increased flow velocity39. Consequently, recommendations have been advocated for the 
increase of velocity criteria corresponding to higher degrees of stenosis following CAS.  
Table 3 shows current recommendations by several clinical laboratories.  
The variability of the recommended criteria values depends upon the balance between 
sensitivity and specificity desired by the laboratory performing the studies. Surveillance is 
usually performed every six months following CAS for at least two years. If the patient 
exhibits contralateral disease, this surveillance may be continued indefinitely. 
 
Stenosis              PSV (cm/sec)        EDV (cm/sec)        ICA/CCA ratio 
 >50%                   >225                              -                           >2.540
                              >240                             -                           >2.4542    
 
 >70%                     >170                         >12041                           -   
                             >350                               -                           >4.7540 
                             >450                              -                           >4.342
 
 >80%                   >340                              -                          >4.1538 
                              >325                         >119                         >4.5339
PSV=peak systolic velocity; EDV=end diastolic velocity  
Table 3. Recommended Velocity Criteria for Restenosis of the ICA following CAS 
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26. Conclusion 
Carotid angioplasty and stenting is very slowly increasing in popularity. Currently, 
approximately 12% of carotid interventions in the United States involve CAS. The major 
limitation in its adaption is the reimbursement climate. Presently, the Center for Medicare 
Services restricts reimbursement for CAS to high risk, symptomatic patients (stenosis > 50%) 
and high risk asymptomatic patients (stenosis >80%) who are on a clinical trial or registry. 
At least one private insurance carrier has elected to support payment for high risk 
asymptomatic patients (>80%) indicating that reimbursement restrictions are gradually 
relaxing. Furthermore, the FDA has approved the use of the Acculink/Accunet carotid stent 
system in asymptomatic patients. These changes in regulatory requirements for CAS 
suggest that eventually, in the not too distant future, this procedure will be approved for all 
patients exhibiting carotid stenosis. Whether CAS should be performed in asymptomatic 
patients remains a controversial issue and will remain a topic in evolution as pharmaceutical 
therapy and life-style changes become increasingly aggressive. 
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